Irreversible electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?
Authors
De Liguori Carino, NO'Reilly, D
Siriwardena, A
Valle, Juan W
Radhakrishna, Ganesh
Pihlak, Rille
McNamara, Mairéad G
Affiliation
Regional Hepato-Pancreato-Biliary Unit, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UKIssue Date
2018-10
Metadata
Show full item recordAbstract
The incidence of pancreatic ductal adenocarcinoma (PDAC) is rapidly increasing. Up to 30% of patients present with locally advanced disease and therefore are not candidates for surgery. Locally advanced pancreatic cancer (LAPC) is an emerging entity lacking in level III evidence-based recommendations for its treatment. Currently, systemic chemotherapy is the main treatment for LAPC. However, due to lack of response or disease progression, downsizing of the tumour, making it resectable is successful in only a small proportion of patients. Radiotherapy is often advocated to improve local disease control if there is stability following chemotherapy. Recently, Irreversible Electroporation (IRE), a novel non-thermal ablation technique, has been proposed for the treatment of LAPC.Citation
Irreversible electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? 2018, 44(10): 1486-1493 Eur J Surg OncolJournal
European Journal of Surgical OncologyDOI
10.1016/j.ejso.2018.07.047PubMed ID
30146253Type
ArticleLanguage
enISSN
1532-2157ae974a485f413a2113503eed53cd6c53
10.1016/j.ejso.2018.07.047